To explore the potential of FCFM by comparing images of the bronchial wall in patients with different pulmonary diseases to pathology specimens of the same area of the bronchial wall.
ID
Source
Brief title
Condition
- Bronchial disorders (excl neoplasms)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The microscopic autofluorescence structure of normal and pathologic bronchial
mucosae will be analysed. Pathology specimens will analyzed by a pathologists
with expertise in pulmonary disorders. Characteristics of images will be
defined, and related to the pathological findings.
Secondary outcome
NA
Background summary
Fibered confocal fluorescence microscopy is a new technique that produces
microscopic imaging of a living tissue through a 1-mm fiberoptic probe that can
be introduced into the working channel of the bronchoscope. The aim of the
present study is to investigate the feasibility of this new technique in
patients with various pumonary diseases
Study objective
To explore the potential of FCFM by comparing images of the bronchial wall in
patients with different pulmonary diseases to pathology specimens of the same
area of the bronchial wall.
Study design
A descriptive feasibility study, in which confocal imaging will be recorded and
bronchial biopsies will be taken during the same bronchoscopy session in
well-characterized patients with an indication for bronchoscopy for varying
reasons
Study burden and risks
The bronchoscopy will be performed by an experienced pulmonologist. The main
inconvenience for the patient is a dry cough and pain at the site of the
nostril through the scoop will be introduced. These complaints are suppressed
by the use of lidocaine spray. The additional images made by confocal
bronchoscopy will add about 10 minuts to the investigation.
Meibergdreef 9
1105 AZ
Nederland
Meibergdreef 9
1105 AZ
Nederland
Listed location countries
Age
Inclusion criteria
Adult patients (18-75 yr) with the following pulmonary diseases will be studied:
1. three patients with a peripheral lung tumor who undergo bronchoscopy as part
of the routine assessment
2. three patients with a previous diagnosis or clinical suspicion of sarcoidosis.
3. three patients with COPD (GOLD II-IV) (smokers or ex-smokers,
postbronchodilator (after inhalation of 400 mcg salbutamol) FEV1/FVC <70%,
reversibility <9%)
4. three patients with asthma (nonsmokers, reversibility of FEV1 > 12% after
inhalation of 400 mcg salbutamol)
Exclusion criteria
Patients who are > 80 years of age or who have previously undergone radiotherapy will be excluded.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL25751.018.08 |